• Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market Growth

SMITHFIELD, R.I., May 29, 2025 — Acclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company’s journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies. This capital infusion will help Acclaro accelerate the growth of its flagship products, UltraClear^® and AuraLux^™ and expedite global market expansion while advancing development of new trailblazing products in its pipeline.

Acclaro Medical’s UltraClear fiber laser is recognized by leading aesthetic professionals as a breakthrough in Total Skin Health that treats multiple skin layers to help reverse the signs of aging and gravity. The first of its kind 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse^™ technology, delivers:

Its precision-engineered capabilities make it the ideal choice for practitioners seeking transformative results with minimal downtime, reduced patient discomfort and speedy healing. Complementing UltraClear, the AuraLux laser leverages the same exclusive Cool Pulse^™ technology and broadens accessibility for aesthetic providers and their patients while maintaining Acclaro’s hallmark quality.

“Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time,” said Acclaro Medical CEO and Co-founder Helen Fang. “This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide.”

Shlomo Assa, President and co-founder of Acclaro Medical, noted: “We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-aging solutions for healthier and younger-looking skin. It greatly enables us to accelerate product development, expand our team, and reach more customers globally – And we’re just getting started!”

The Series B funding will allow Acclaro Medical to leverage decades of Accelmed’s operational and financial expertise, alongside 3E Bioventures’ disciplined efficiency. Acclaro Medical is poised to execute its strategic plans and realize its vision of revolutionizing the aesthetic industry. These efforts will further cement the company’s position as a leader in providing innovative, patient-centered skin health solutions.

“Acclaro’s unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device,” stated Daniel Cohen, Accelmed’s venture partner with extensive experience leading successful Medtech & Biotech investments over the last 20 years. “Accelmed Partners is thrilled to lead this round of financing and accompany Acclaro’ s management in this fantastic journey.”

About Acclaro Medical

Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today’s unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry. Its proprietary 3DMIRACL^™ and Laser Coring^™ skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit https://ultraclearlaser.com/about/acclaro-medical/.

About Accelmed Partners

Accelmed, a leader in healthcare technology investing, is renowned for its private equity approach to a sector traditionally dominated by venture and early-stage growth firms. Its team of experienced industry veterans and company builders work closely as a trusted partner with portfolio management to improve operations, upgrade product portfolios, and strengthen commercial organizations. Accelmed’s support and resources are designed to help portfolio companies like Acclaro Medical elevate its technology and achieve enduring success. The investment firm currently manages over $630 million of equity capital. For more information, please visit https://accelmed.com/about.

Media Contact:
Nadine Tosk
Tosk Communications for Acclaro Medical
[email protected]; 504.453.8344

SOURCE Acclaro Medical Corporation

The company has quickly become the system of record for the next-generation of finance teams, including those at Windsurf, Decagon, Postscript, and more

NEW YORK, May 28, 2025 — Rillet, the AI-native ERP (enterprise resource planning) platform, today announced $25M in Series A funding led by Sequoia Capital. This round, which comes 10 months after Rillet’s last fundraise, includes existing investors First Round Capital, Creandum, Susa Ventures and top angels, such as former NetSuite CFO, Ron Gill and Lee Kirkpatrick, former Twilio CFO.

Today, many accounting teams are reliant on legacy ERP systems and tools from the 90s, preventing them from fully adopting AI. Products like NetSuite are slow, outdated, highly manual and often bloated and complex from extensive customization. Full utilization of AI requires a single source of truth with clean, accurate data.

Rillet has rebuilt the general ledger to redefine the ERP for the AI age. The platform integrates directly with best-in-class tools, including Salesforce, Stripe, Ramp, Brex and Rippling. Rillet AI agents then automate key accounting workflows from accruals to reconciliation to board reporting and more.

“We’re a team of accountants building for accountants. This means everything from the reports to the workflows is tailor-built for the challenges CFOs and controllers deal with on a daily basis,” said Rillet CEO and founder, Nicolas Kopp.

Rillet empowers customers to close their books in hours rather than weeks, providing fully reconciled financial data in real time to enable faster and better decision making. Leaders no longer need to wait weeks after the month ends to see how the business is performing. This means that leaner, more efficient accounting teams can then focus on higher leverage, more strategic work.

“ERP is one of the largest software categories, yet it has remained virtually untouched for the last decade because reimagining the financial backbone of a business is incredibly complex,” said Julien Bek, the Sequoia partner who led the firm’s partnership with Rillet. “Nicolas has brought together a world-class team to tackle this challenge, combining deep domain expertise with AI-native technology to rebuild the foundation of the CFO suite.”

Sequoia, which is known for partnering with category-defining fintechs like Stripe, Block, and more, has several ex-CFO investing partners. Roelof Botha, managing partner at Sequoia and prior CFO of PayPal added:

“Rillet has rethought the general ledger to automate accounting with real-time integrations and AI-driven workflows, allowing finance teams to work smarter and businesses to scale faster. This modern approach helps CFOs capture the full value of AI, and, ultimately, positions Rillet as the system of record for the next generation of finance teams.”

Since launching in 2024, Rillet has seen incredible traction with revenue growing 5x year-on-year and the platform processing billions in transactions. Nearly 200 customers including fast-growing companies like Windsurf, Decagon and Postscript have implemented Rillet to transform their accounting processes.

Windsurf, one of the fastest growing AI companies, runs all their accounting on Rillet: “Rillet feels like it was tailor built for Windsurf and our complex accounting needs. We have a unique blend of products and revenue models and are growing at lightning speed; Rillet handles all of it effortlessly,” said Windsurf VP of Finance, Adam Strouss.

This new funding and support from Sequoia will allow Rillet to further accelerate the development and deployment of AI within the platform and enable them to further build out the go-to-market and customer support functions.

SOURCE Rillet

BETHESDA, Md., May 28, 2025 — The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and MDC Studio, Inc (MDC) are proud to announce their groundbreaking collaboration through the HJF-MDC Venture Fund LLC.

This collaboration aims to revolutionize medical technology development and commercialization, benefiting military and civilian health care sectors.

The HJF-MDC Collaboration

This new initiative seeks to grow existing collaborations to accelerate the development and commercialization of dual-use medical technologies for military and civilian applications. As part of this initiative, MDC Studio has established a satellite office within HJF’s innovation facility in Bethesda, Maryland.

Introducing the HJF-MDC Venture Fund

HJF and MDC formed the HJF-MDC Venture Fund, as an independent entity that aims to invest in a diversified portfolio of early-stage companies commercializing military medical technologies with civilian applications. HJF is participating as a non-voting member of the Fund with a minority interest. The Fund’s focus areas include medical devices, wearables for health, and rehabilitation / assistive robotics. The Fund will be overseen by a Board of Managers, who will make investment decisions based on objective selection criteria, including alignment with military medical needs, benefits to civilian health, risks, and expected returns.

The Fund’s Board of Managers includes:

• Dr. Gil Blankenship, Ph.D., is the Founder of MDC Studio. Over his career, Dr. Blankenship transitioned from a researcher in applied mathematics to an entrepreneur building technology companies, including three successful exits. He retired from the University of Maryland School of Engineering in 2022.
• Dr. Jonathan Pearl, M.D., is a Partner and Medical Advisor in the MDC Studio. Dr. Pearl is an Associate Professor of Surgery in General and Oncologic Surgery at the University of Maryland School of Medicine. Dr. Pearl is a Veteran of the United States Navy with several tours of duty and distinguished service awards.
• Dr. Lester Martinez-Lopez, M.D., M.P.H., served as the Assistant Secretary of Defense for Health Affairs. In this role, he was the principal advisor to the Secretary of Defense and the Undersecretary of Defense for Personnel and Readiness for all Department of Defense health and force health protection policies, programs, and activities. Dr. Martinez-Lopez, a family medicine physician, retired from the Army as a Major General and headed the Army Medical Research and Materiel Command, where he directed the Army’s worldwide medical research, acquisition, and logistics program.
• Dr. Leonard Mills, Ph.D., C.F.A., had a lengthy career as an investment manager at large financial institutions and private equity funds. In 2016, Dr. Mills founded PI Analytics Investment Adviser, specializing in venture capital investments.

The HJF-MDC Venture Fund is raising $20 million to invest in new companies for its expanding portfolio of investments in dual-use startups with high potential.

The HJF-MDC Venture Fund represents a significant step forward in advancing medical technologies that benefit both military and civilian healthcare by supporting innovation and commercialization in dual-use medical technologies.

About HJF

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a Congressionally authorized global nonprofit organization with the mission to advance military medicine. Since 1983, HJF has been a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. With more than 3,000 employees, HJF manages over 800 awards and 1,500 active research protocols, focusing on combat casualty care, infectious disease, cancer, neurological, and clinical and rehabilitative medicine.

About MDC

Established in 2016, MDC Studio is a Maryland-based startup studio that collaborates with medical professionals, engineers, and entrepreneurs to translate intellectual property into market-ready products. MDC licenses technologies from technology transfer offices and develops its own inventions, focusing on medical device innovations. MDC has successfully raised nearly $27 million in contracts, grants, and investments for its portfolio companies.

For more information, please contact:

Stephen Dalal, D.V.M.,
HJF Vice President, U.S. Research Development
HJF-MDC Venture Fund LLC.
Email: [email protected]
Phone: +1 (240) 425-5699

SOURCE Henry M. Jackson Foundation for the Advancement of Military Medicine

SAN FRANCISCO, May 28, 2025 — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), today announced the completion of an oversubscribed USD $50 million Series B+ financing round, led by an existing, industry-leading VC investor, with strong participation from Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, and Sherpa Capital.

This financing follows AusperBio’s Series B round completed in December 2024 and reflects continued investor confidence in the company’s lead product, proprietary platform, and strategic direction. The proceeds will support the ongoing clinical development of AHB-137, a novel unconjugated antisense oligonucleotide for chronic hepatitis B (CHB), including planned Phase II trials outside of mainland China. The funding will also enable scale-up of commercial manufacturing partnerships and support the company’s long-term pipeline growth.

Dr. Guofeng Cheng, co-founder and CEO of AusperBio, commented, “We are greatly honored by the continued support from our investors. It’s a strong vote of confidence in our vision and the progress we’ve made so far. This new funding gives us the momentum to move AHB-137 into the next phase of global development. We are committed to stay focused on our mission to deliver a functional cure for chronic hepatitis B and bring life-changing therapies to patients worldwide.”

Dr. Chris Yang, co-founder and CSO, added, “We are strongly encouraged by the recent progress of AHB-137, particularly the positive Phase IIb data presented at the EASL Congress in Amsterdam. With strong investor support, the AusperBio team is fully motivated to continue our clinical strategies and efforts to bring new treatment options to people living with CHB.“

AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms for this serious chronic disease.

About AHB-137

AHB-137, a novel unconjugated antisense oligonucleotide (ASO) designed using AusperBio’s proprietary Med-Oligo™ ASO technology platform, is being developed to achieve a functional cure for chronic hepatitis B. Its clinical development has generated compelling data, with key preclinical and clinical results presented at leading conferences such as EASL (2023, 2024, 2025) and AASLD (2024). This novel dual-mechanism ASO has completed its global Phase 1b trial and is currently advancing through multiple Phase 2 studies in China. Supported by a clear global development strategy, AHB-137 is progressing rapidly toward delivering a potential cure for HBV.

About AusperBio.

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for chronic hepatitis B infection. The company has developed a proprietary Med-Oligo^™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-Oligo™ Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.

For further information, please contact:

Media Contact
Email: [email protected]

Investor Relations Contact:
Tel: 650-888-1756 (US)
Email: [email protected]

SOURCE AusperBio Therapeutics Inc.

1,000+ locations. Industry-leading 85 NPS. A better way to stay.

SAN FRANCISCO, May 28, 2025 — The short-term rental market is massive, but it remains deeply fragmented. For guests, every booking feels like a gamble. For owners, managing a property is anything but passive. The result is an experience that’s often inconsistent, unsupported, and unreliable. Consistency and quality is needed now more than ever. Wander is fixing that—end to end.

Today, the company announced a $50 million Series B funding round, co-led by QED Investors and Fifth Wall with participation from Redpoint Ventures, Uncork, Starwood, and Breyer Capital and many other returning and new investors. The capital will accelerate Wander’s expansion and deepen its investment in WanderOS, its proprietary AI operating system that manages logistics and guest needs with hotel-grade consistency, at scale.

“We are excited to continue to support John Andrew and the whole Wander team by co-leading their Series B round. Wander has built a world-class brand with industry-leading software to bring the Wander experience to thousands. Reviews have been overwhelmingly positive with NPS scores in the 70s and 80s. In just one year, the company has signed over 1,000 homes and looks to continue adding coverage to the map. WanderOS has enabled this tremendous growth while making the process for owners to onboard to Wander seamless,” said Chuckie Reddy, Partner at QED Investors.

“The short-term rental market represents a massive and under-optimized asset class, and Wander is uniquely positioned to lead it into its next chapter,” shared Dan Wenhold, Partner, Fifth Wall. “By combining premium inventory, a trusted brand, and category-defining software, Wander is setting a new standard for consistency and scale in a historically fragmented space—delivering an end-to-end, high-touch, high-quality travel experience. We’re proud to co-lead this round and to continue backing John Andrew and the Wander team as they redefine the future of travel.”

A Better Way to Stay. A Better Way to Find Your Happy Place.

Wander is building the first true brand in short-term rentals—one that combines the dependability of a luxury hotel with the warmth and character of a thoughtfully designed home. Rather than trying to capture the entire market, Wander focuses on the top 5% of properties, the homes that already drive 30% of the industry’s revenue. These properties are then elevated through WanderOS, which brings consistency and operational excellence across every single touchpoint of the guest and owner experience.

With Wander, every stay includes:

• Spaces that look even better than the photos
• Premium beds, fast Wi-Fi, and seamless check-in
• Smart, always-available concierge support powered by humans and AI

In Q1 2025, Wander earned an industry-leading customer NPS of 85, demonstrating that trust and satisfaction are not only possible in this category: they’re scalable.

Scaling Hospitality with AI

WanderOS is transforming the way short-term rentals are operated, automating everything from listing creation to maintenance coordination. Wander is on track to automate 95% of operational tasks within the next 18 months.

As of April 2025, Wander has more than 1,000 incredible homes live, up 14x year over year, and has seen:

• 35,000+ total nights booked as of Q2 2025
• A 92.1% customer satisfaction rate and a 9.3/10 average trip rating
• 27% repeat customer booking rate

This growth is powered by Wander’s ability to deliver a unified platform that addresses guest experience, owner satisfaction, and operational efficiency, all at scale.

Positioned for Global Impact

Wander is targeting the $35B+ tier of luxury homes across North America and beyond – the properties that guests remember and owners seek to maximize. With this Series B funding, Wander will expand into new markets, invest further in AI-powered operations, and continue building a global brand grounded in quality, trust, and technology.

In a fragmented category, Wander is stitching it all together. Unrelenting brand standards. Customer delight. Distribution. Operations. All under one roof. For those who believe short-term vacation rentals should be more reliable, more enjoyable, and more inspiring, Wander is building the future.

Find your happy place.
Wander.com

Contact
Cristin Culver
[email protected] 

SOURCE Wander

Software investment firm continues to back ambitious founders with shared values, long-term vision, and a focus on building enduring market leadership.

KANSAS CITY, Mo., May 28, 2025 — Five Elms Capital, a software-focused growth equity firm, today announced the October 2024 closing of Five Elms VI with $1.1 billion in total commitments, the largest fund in firm history. The oversubscribed fund drew strong participation from both existing and new limited partners and meaningfully expanded Five Elms’ global investor base. With the close of Fund VI, Five Elms has increased assets under management to over $3 billion and is empowered to continue acting as a trusted partner for fast-growing, founder-led software companies.

In Fund VI, Five Elms will continue partnering with software companies that have proven business models, differentiated products, strong customer loyalty, and are poised for meaningful scale. These companies typically have strong foundations and are at a growth inflection point, where focus turns to expanding leadership teams, creating scalable operations, and enhancing products to stay ahead of competitors. Founders typically choose Five Elms for its unique culture and hands-on support, backed by nearly two decades of experience partnering with over 70 software companies globally.

“We’re very grateful for the continued support of our existing investors and thrilled to welcome new limited partners to Fund VI,” said Fred Coulson, Founder and CEO of Five Elms Capital. “Since 2006, we’ve partnered with founders who have built strong products and distinct company cultures to help them scale into category leaders. Our team is purpose-built to support that transition and is ready to roll up their sleeves alongside our partners.”

Five Elms’ value creation team is a foundational part of the firm’s strategy and supports portfolio companies with practical, hands-on expertise as they scale. The team includes 17 in-house software operators with deep experience across executive recruiting, finance, sales and marketing, customer success, product development, and AI enablement. Built to complement founder-led organizations, the value creation team works closely with portfolio company management to accelerate revenue growth, strengthen customer retention, optimize product & AI-enablement, and implement scalable operations to support long-term success.

Five Elms VI has already made four platform investments in high-growth software companies:

• Magma Math – AI-enabled digital learning platform helping students and teachers engage with math through intuitive, open-ended problem solving.
• RoomPriceGenie – revenue management solution empowering independent hotels to optimize pricing through automation and AI.
• Pathify – student experience platform connecting higher education institutions with their students through personalized communication and workflow tools.
• Motivity – practice management and data platform purpose-built for behavioral health providers.

“As a founder, it was important to find a partner who understood what we were building—not just in terms of product, but in how we think about team and culture,” said Henrik Appert, Founder and CEO of Magma Math. “With Five Elms, we found a team that shares our values, brings meaningful operating experience, and is willing to engage on the things that actually move the business forward. They’ve been thoughtful, collaborative, and focused on helping us scale the right way.”

Evercore Private Funds Group acted as the exclusive global placement agent for Five Elms VI, and Foley & Lardner LLP served as fund formation counsel.

Please direct all inquiries to [email protected].

About Five Elms
Five Elms Capital is a growth investor in software businesses that users love, providing capital and resources to help companies accelerate growth and further cement their role as industry leaders.

With over $3 billion in assets under management and a team of over 80 professionals, Five Elms has invested in more than 70 software platforms worldwide. Beyond providing capital, Five Elms delivers strategic and operational expertise, focused on executing initiatives that move the needle on growth, retention, product, and AI to set companies up for long-term success. For more information, visit fiveelms.com.

SOURCE Five Elms Capital

RADNOR, Pa., May 28, 2025 — Connor McMahan today announced the launch of Virent Capital, a private equity firm headquartered in Radnor, Pennsylvania, focused on partnering with founder-led services and consumer companies across the U.S. lower middle market.

Virent was founded on the belief that the next generation of private equity success will be driven by deep sector insight, technology enablement, and hands-on value creation, not simply capital. The firm blends a research-driven, thesis-led investment approach with Virent Drive™, a proprietary technology-enabled operating platform powered by an elite network of experts and capabilities designed to help companies modernize, scale, and accelerate growth.

While Virent will focus primarily on services and consumer businesses, it will selectively partner in other sectors where digital enablement and operational modernization can meaningfully accelerate performance.

Connor McMahan is the Founder and Managing Partner of Virent Capital.  He brings more than a decade of experience leading investments as a former Partner at L2 Capital. “Virent was created to meet the needs of founders looking for more than just capital. We are building a firm purposefully designed for this segment of the market, offering the structure, resources, and strategic support to help companies scale with focus and integrity,” noted McMahan.  “I am grateful to my mentor and anchor investor, Bob Levine, and to our senior advisors for their belief in my vision.  Their support and partnership are instrumental to what Virent is building.”

Virent targets control investments in U.S.-based companies with under $8 million of EBITDA. The firm is particularly well-suited for businesses seeking their first institutional partner, especially those undergoing an analog-to-digital shift, and brings over a decade of strategic and operational investing experience. At a time of rapid technological transformation, Virent delivers the ability to unlock growth through rigorous strategy and operational improvements, as well as proprietary capabilities in IoT (Internet of Things), artificial intelligence and machine learning, application development, ecommerce and performance marketing—a level of enablement that remains highly differentiated in lower middle market private equity settings.

Bob Levine, Founder of L2 Capital, has committed capital to support the firm’s long-term vision and growth, and commented on Virent’s launch: “Connor and I have worked closely together for more than a decade, and I’ve had the opportunity to see his instincts and discipline as an investor play out time after time. He has consistently earned the trust of founders and delivered strong outcomes for all stakeholders. My family and I are proud to support him in this next chapter and are confident in his ability to grow, build, and succeed with Virent over the coming years.”

About Virent Capital
Virent Capital (www.virentcap.com) is a private equity firm focused on digitally enabling the next generation of founder-led services and consumer companies. Headquartered in Radnor, PA, the firm targets control investments in U.S. lower middle market businesses, typically those with under $8 million of EBITDA. Virent combines a thesis-led investment model with Virent Drive™, its proprietary growth platform that leverages a curated network of technology, digital, and operating partners to accelerate performance and build lasting value.

Media Contact
Emma Dougherty
[email protected] 
(484) 222-3419
www.VirentCap.com

SOURCE Virent Capital

HealthX Ventures backs Minset’s intelligent agent, Mia, to automate claims, denials, and payments across the revenue cycle.

BOSTON, May 28, 2025 — Minset, the company behind the first multi-skilled agentic AI platform purpose-built for healthcare revenue cycle management, today announced a seed funding round led by HealthX Ventures, a leading digital health venture firm. The funding will accelerate product development and scale go-to-market efforts as Minset expands its platform to more healthcare organizations worldwide.

As part of this next phase of growth, Minset also announced the appointment of Mike Luessi to lead Growth & Operations. Luessi joins CEO Trey McMillian and CTO Matt Scott, bringing more than 20 years of experience building and scaling high-growth companies. This rounds out an experienced leadership team with deep expertise at the intersection of AI R&D, and scaling complex platforms in healthcare and enterprise technology.

“The investment from HealthX and the addition of Mike to our team accelerates our mission to fix one of healthcare’s toughest financial challenges: Revenue Cycle Management,” said Trey McMillian, CEO of Minset. “We built Minset to end the chaos, not manage it. Our agentic AI platform doesn’t just track revenue work, it does the work. Mia, our multi-skilled AI agent thinks, reasons, and acts to get healthcare organizations paid.”

Meet Mia: Multi-Skilled Agentic AI That Gets Healthcare Paid

Minset is pioneering a new category in healthcare operations: the Autonomous Revenue Cycle (ARC). At the heart of the platform is Mia, Minset’s intelligent, multi-skilled agentic AI. Unlike other platforms that rely on a complex mix of orchestrated single-skilled agents and other tools, Mia handles it all. From coding and denials to payments, Mia’s got it – no bots to wrangle nor micromanagement required.

Mia learns, reasons and resolves revenue cycle issues quickly, helping providers prevent denials, recover revenue, and operate at scale. She works 24/7 and continuously evolves to keep up with payer rules, regulatory shifts, and operational complexity.

Helping over 300 healthcare organizations to date, Mia powers three core products: mCoder to automate medical coding, mDenials to manage denials, and m360 for patient engagement (propensity to pay).

From hospitals and clinics trying to get paid for the care they provide, to insurers overwhelmed by administrative burden, Mia brings intelligence, speed, fairness, and transparency to healthcare finance.

“We are thrilled to partner with Minset to create cutting-edge AI technology to transform healthcare operations,” said Jan Grimm, CEO of Savista, a leading healthcare revenue cycle management services company. “Our combined expertise will empower healthcare organizations with smarter, faster, and more efficient revenue cycle solutions. By partnering on AI solutions, including AI agents, we are poised to modernize the RCM space, delivering unprecedented value to healthcare providers.”

HealthX Ventures, known for investing in companies modernizing healthcare infrastructure, sees Minset as a step-change in the application of AI to healthcare financial operations.

“Minset isn’t automation, it’s autonomy,” said Kristi Ebong, Partner at HealthX Ventures. “This is the first platform we’ve seen that truly replaces the manual work of the revenue cycle, without requiring providers to rip and replace their core systems. The team is solving a real problem with real AI, and the traction speaks for itself.”

“Traditional systems have hit their ceiling. Minset gives healthcare a new ceiling—or better yet, removes it. It delivers clarity where there was chaos, and outcomes where there were only excuses. They’re building what could become the most important financial infrastructure company in healthcare,” said Ebong.

The Minset Platform integrates seamlessly with major EHR and claim workflow systems, replacing spreadsheets, queues, and legacy processes, with a multi-skilled AI agent who’s always on, always improving, and always delivering outcomes.

To learn more, visit www.minset.ai

Media Contact: Mike Luessi  [email protected]

About Minset

Minset created the first multi-skilled agentic AI platform purpose-built for healthcare revenue cycle management. Designed to think, reason, and act across the entire revenue lifecycle, Minset’s platform helps healthcare organizations get paid, automatically, accurately, and at scale. Its suite of intelligent products: mCoder for autonomous medical coding, mDenials for denials management, and m360 for patient engagement, replaces manual work and fragmented tools with one, state-of-the-art agentic AI system. Founded by experts from Google, Microsoft, Optum and Salesforce, and backed by HealthX Ventures, Minset is helping providers reclaim time, reduce burnout, and achieve financial clarity in an increasingly complex environment. To learn more, visit www.minset.ai.

About HealthX Ventures

HealthX Ventures is a digital health-focused venture capital firm investing in companies that make healthcare more efficient, affordable, and accessible. The firm partners with founders building scalable, enterprise-grade technology solutions that move the industry forward. Learn more at www.healthxventures.com.

SOURCE MInset AI, Inc

• Cerby to use new capital to further innovate its entire solution suite and scale operations in North America and EMEA region.
• Round was led by DTCP with participation from Okta Ventures, Salesforce Ventures, and Two Sigma Ventures.

SAN FRANCISCO, May 28, 2025 — Cerby, the fastest-growing platform for identity security automation globally, has announced today a $40 million Series B funding round. The round was led by DTCP with participation from existing backers including Okta Ventures, Salesforce Ventures, and Two Sigma Ventures.

As SaaS, cloud, mobile, and on-premise applications continue to proliferate, the enterprise attack surface has expanded dramatically, making the need for autonomous, scalable, state-of-the-art identity security solutions bigger than ever.

Cerby is the first to automate the full identity lifecycle for disconnected applications—from credentials and authentication to lifecycle management and privileged access. It works horizontally across Enterprise Password Management (EPM), Identity and Access Management (IAM), Identity Governance and Administration (IGA), and Privileged Access Management (PAM) systems, helping customers extend protection to the applications and user identities that traditional tools can’t reach.

Cerby will invest the new capital to expand the Cerby Application Network in response to growing customer demand. This will include continued investment in the company’s agentic AI capabilities and making the platform extensible. Cerby will also use the latest funding to further innovate its entire solution suite while scaling go-to-market operations in North America and EMEA.

As part of this strategy, Cerby is prioritizing growth in key markets such as Germany, France, the UK., along with strategic Middle Eastern regions, where regulatory pressure and increasing enterprise complexity are accelerating demand for solutions that secure disconnected applications at scale.

Belsasar Lepe, co-founder and CEO of Cerby, comments: “From day one, we’ve been laser-focused on eliminating the operational burden and security risk created by manual identity workflows—automatically, intelligently, and at scale. We’re building a world where identity security is fully automated—eliminating human error and ensuring no app is left behind.”

Lance Matthews, Partner at DTCP, shares: “We are thrilled to be partnering with Cerby to support them in this exciting new stage of growth. The identity security industry is undoubtedly overdue for transformation—and Cerby is leading that shift with a true platform approach. I am confident that together with Belsasar and the team, Cerby will be able to execute on their bold vision, continuing to build on their proven solutions and unique platform.”

Since raising its Series A less than 20 months ago, Cerby has 10x’d ARR and grown its customer base 5x. The platform now automates identity workflows across more than 2,000 applications and supports over 100 organizations worldwide.

Global brands, including L’Oréal, Fox, Allstate, Chime, and Dentsu rely on Cerby’s platform to automate critical security workflows across their most complex environments.

Media Contact

Kekst CNC: [email protected]

About Cerby

Cerby is the identity automation platform purpose-built to secure disconnected applications—those that fall outside the reach of traditional identity security tools. By integrating with existing IAM, IGA, and PAM systems, Cerby brings centralized access controls, automates manual security tasks, and extends governance across your entire application ecosystem. IT and security teams gain complete visibility and control, reducing risk and operational overhead. Founded in 2020, Cerby is backed by leading investors and trusted by global enterprises.

Meet the Cerby team at the Identiverse conference in Las Vegas from June 3–6 at Booth #709, or book a meeting with our team to learn more.

About DTCP

DTCP is an investment management firm with $3 billion in assets under management and over 50 professionals. DTCP has offices in San Francisco, Hamburg, Frankfurt, Berlin, London, Luxembourg, and Tel Aviv.

DTCP Growth invests in leading companies with a focus on cloud-based enterprise software. The team has made over 42 investments in US, Europe, and Israel, with notable investments including Arctic Wolf Networks, Auth0 (acquired by OKTA), Guardicore (acquired by Akamai), Fastly (NYSE: FSLY), Cohere, LeanIX (acquired by SAP SE), Pipedrive (acquired by Vista Private Equity), and Signavio (acquired by SAP SE). For a full list of portfolio companies please refer to www.dtcp.capital/growth-equity

“DTCP” is a trading name for companies for alternative investments as well as distribution, fund advise and service companies. The relevant legally responsible entities, which offer products or provide services to clients or the respective funds, are named in the relevant contracts, marketing documents or other product-specific information.

For more information on DTCP, visit dtcp.capital.

SOURCE Cerby